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Abstract: For over one decade Glycoproteins IIb/IIIa inhibitors (GPI) have been administered to prevent coronary artery 
thrombosis. Initially these agents were used for acute coronary syndromes and subsequently as adjunctive pharmacother-
apy for percutaneous coronary interventions (PCIs).  
Most benefit of GPI emerged from reduction of ischemic events: mostly non-q-wave myocardial infarctions (NQWMIs) 
during PCI. However, individual randomized clinical trials could not demonstrate that any of these agents could signifi-
cantly reduce mortality in any clinical subset of patients. Studies of employing prolonged oral GPI administration resulted 
in excessive death. The non-homogenous statistically-significant reduction of ischemic endpoints was accompanied by an 
excess of bleeding, vascular complications, and thrombocytopenia. The clinical and ecomomic burden of major bleeding 
and thrombocytopenia is substantial. The ACUITY trial has initiate a new debate regarding the efficacy and safety of GPI.  
Selective “patient-tailored” use of GPI limited to moderate-high risk PCI patients with low bleeding propensity is sug-
gested. Research of new algorithms emphasizing abbreviated GPI administration, careful access site and bleeding surveil-
lance, in conjunction with lower doses of unfractionated heparin or new and safer anti-thrombins may further enhance pa-
tient safety.  
INTRODUCTION 
  GPI are used as adjunctive therapy for 60-70% of PCIs 
performed in the USA. This review attempts to summarize 
the current data on the efficacy and safety of these agents in 
PCI. In view of the data, potential modification of treatment 
algorithms is discussed.  
EFFICACY OF GPI (TABLE 1)  
Mortality Data 
  None of the individual GPI randomized clinical trials 
(RCTs) was ever able to demonstrate statistically-significant 
mortality reduction in any clinical setting. However some 
RCTs detected a favorable trend towards 20-30% relative 
risk reduction mortality in certain patient subsets. In order to 
prove statistically significant mortality benefit certain publi-
cations employed sub-analysis, while others have engaged in 
meta-analysis. The latter bring to the scientific arena com-
plex validity concerns when performed quantitatively (due to 
increased risk of type I error). The need to adjust thresholds 
for statistical significance to account for multiple investiga-
tions or for potential heterogeneity is subject for methodo-
logical debates. Moreover, “publication bias” can further 
erode the meta-analysis validity: studies with unfavorable 
outcome are discontinued, not reported or remain unpub-
lished, and if published are omitted from meta-analysis. As 
an example: 4 phase 3 RCTs of oral-GPI in ACSWSTE 
[1,2], which together enrolled 33,326 patients, demonstrated 
31% excess mortality in the GPI arm (OR = 1.31; 95% CI: 
1.12 to 1.53; P= 0.0001). Moreover the incidence of myo-
cardial infarction increased (OR = 1.16; 95% CI: 1.03 to 
1.29). These studies as well as other studies of oral GPI were 
not incorporated into the following meta-analysis.  
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  The applicability and relevance GPI-RCTs on the con-
temporary cardiovascular arena is further diminished by cer-
tain issues (a) Enrollment bias: Certain patients were delib-
erately excluded from most these studies: especially patients 
who were considered high cardiovascular or bleeding risk 
(elderly, patients with heart renal or hepatic failure, history 
of bleeding, renal insufficiency or cerebrovascular disease). 
(b) Design bias: Most of the trials have carefully tracked 
ischemic events. The most frequently reported endpoint was 
post-PCI enzyme rise (CPK>2-3 times the upper limit of 
normal) that were named “myocardial infarctions”. The 
medical and economic impact of these surrogate laboratory 
end-points on patient outcome (like cardiovascular mortality, 
medical costs, length of hospital stay and patient well-being) 
was not usually ascertained. (c) Accounting for adverse 
events: Attempt to prospectively account for the clinical 
consequences of various drug-related adverse events (includ-
ing: minor and major bleeding, vascular complications, 
transfusions thrombocytopenia and allergic reactions) on 
patients’ outcome was not diligently delineated. (d) Current 
applicability and relevance: From the time the studies were 
executed the practice of interventional cardiology has under-
gone considerable change: with the inception of routine ver-
satile stenting, pre-PCI high dose (600 mg) clopidogrel, new 
safe and effective anti-thrombins, and optimal stenting en-
hanced by and pre and post-PCI lesion assessment by in-
travascular ultrasound and pressure wire.  
  As mentioned before individual GPI RCTs failed to 
demonstrate significant mortality reduction. The trend of 
reduced mortality and ischemic events was not homogenous 
across patient subsets and studies. In the absence of signifi-
cant treatment effect on mortality in individual RCTs meta-
analysis were introduced:  
  At 2003 a meta-analysis [3] of 12 trials (and over 20,000 
PCI patients) demonstrated a statistically significant mortal-
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0.024 and number needed to treat to save 1 life was 357), 
however at 6 months this beneficial effect was diminished. 
(OR was 0.84 (95% confidence interval 0.69 to 1.03, p = 
0.087). This meta-analysis was published 2 years after a 
former (2001) negative meta-analysis [4].  
  Meta-analysis [5] of 19 PCI RCTs (6 STEMI trials, the 
rest were ACSWSTE and elective or mixed-cohort PCI) that 
enrolled 20,137 patients (11,444 in abciximab studies), set 
the primary outcome as death at 1 and 6 months. There was a 
0.47% and 0.61% absolute mortality reduction at 1 and 6 
months (“number needed to treat” to save one life was 320 
and 220 respectively). Mortality benefit at 6 months had a 
tight confidence interval (RR 0.79, 95% CI 0.64-0.97). 
While abciximab [6] and eptifibatide showed favorable mor-
tality trends tirofiban had negative mortality trend. Stent 
placement was the initial PCI approach in only one fourth of 
this patient cohort. Although the authors claim the benefit 
was not device-specific, certain studies suggest that GPI 
benefit is augmented by devices like directional atherectomy 
[7] or balloon angioplasty [8] especially in the setting acute 
coronary syndromes, and less likely to affect the results of 
stenting or rotational atherectomy. Any myocardial infarc-
tion at 30 days was reduced by 2.3% (4.6% versus 6.9%, RR 
0.63, CI 0.56-0.70). Major bleeding was significantly in-
creased by 1.4% (4.6 versus 3.2, RR 1.26 CI 1.09-1.46). 
There was no accounting for minor bleeding, thrombocy-
topenia, vascular complications, transfusions or allergic reac-
tions. Even when all 6 STEMI studies were pooled together 
no significant treatment effect of mortality was detected [9].  
  Meta-analysis of 6 RCTs of GPI in ACSWSTE [10] in-
cluded 31,402 patients (18,297 on GPI) of which 24% un-
derwent PCI at 30 days suggested that: (a) 30-day mortality 
(3.4% versus 3.75, p=0.14, OR 0.91 (95% CI of 0.81-1.03), 
and non-fatal myocardial infarction (defined as CPK rise 
exceeding 2-3 times the upper limit of normal) (7.4% versus 
8.1%, OR=0.92, 95% CI 0.81-1.03) were not significantly 
reduced. (b) While Patients with elevated Troponin, ischemic 
ST depression on the EKG and males derived more benefit 
from GPI, in women (n=11,003) mortality actually in-
creased. (c) GPI use was associated with a significant 1.1 % 
increase in major bleeding (1.4 versus 2.5%, OR 1.64, 95% 
CI 1.36-1.97).  
  A recent [11] multivariate and propensity analyses com-
pared the frequency of death, reinfarction, and major bleed-
ing during hospitalization in 38,691 patients with NSTEMI 
who were enrolled in the National Registry of Myocardial 
Infarction (NRMI)-4 (2000– 2003). Of these, 65% received 
GPIs only, 16.1% clopidogrel only, and 18.8% received 
both. The composite end point of death, reinfarction, and 
major bleeding was higher among patients who received 
both drugs rather than clopidogrel alone (odds ratio 1.31, 
95% confidence interval 0.99 to 1.72). 
Ischemic Events 
  Most GPI studies have shown statistically significant 
reduction in ischemic events in the GPI arm. Most of these 
ischemic events were non-Q-wave myocardial infarctions 
(NQMIs). This beneficial effect was especially robust in 
high-risk patients (usually patients with ischemic ST depres-
sion, positive cardiac bio-markers or diabetics). Although, 
some non-RCTS [12] have claimed that even prevention of 
mild troponin leaks is associated with better outcome; this 
was never confirmed and actually contradicted by large scale 
RCTs: these small CPK leaks (or myocardial infarctions) 
have never translated into meaningful excess in 30 day or 6 
months mortality. It is possible, that these “laboratory 
events” carry a very limited clinical impact just like the rise 
of troponin observed routinely after radiofrequency arrhyth-
mia ablation or in >40% of PCIs [13]. 
Table 1.  GPI RCTs- Effect on 1-6 Months Mortality 
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*STEMI- ST elevation myocardial infarction  
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Other Drug Claims 
  Other favorable effects of GPI, like improving pre-PCI 
TIMI flow, or TIMI frame count [14] or improving micro-
circulation perfusion in STEMI, have not translated into 
meaningful benefits in patient outcome. Neither abciximab 
nor any other GPI have ever demonstrated favorable effect 
on in-stent restenosis [15]or late re-intervention. 
SAFETY OF GPI  
Effects on Bleeding and Vascular Complications 
  Brown [16] reported FDA data on 450 deaths associated 
with GPI use: 44% were considered to be definitely or 
probably related to the use of GPI inhibitors. The author 
suggested that patients treated in normal clinical practice 
might pose a greater bleeding-risk than those treated enrolled 
in RCTs. 
  Bleeding became the most common serious complication, 
and among the most costly complications of PCI (incre-
mental cost of hospitalization > $10,000, due to prolonged 
hospital stay and the use of additional resources). Bleeding is 
associated with excessive morbidity and mortality, contribut-
ing to additional treatment costs beyond those directly attrib-
utable to correcting the bleeding complication [17]. That 
report claims that the favorable current trend of reduced 
heparin dose (associated with reduced bleeding complica-
tions) is counteracted by routine administration of GPI 
(which results in excess of bleeding complications and 
thrombocytopenia).  
  The ACUITY [18] investigators and others, employed 
the concept of “net clinical benefit” which is the defined as 
the total number of ischemic endpoints and major bleeding 
events in each treatment arm. This concept is easily applica-
ble but grossly oversimplifies and consequently distorts the 
true impact of the various events. One can not compare hier-
archic impact of QWMI or major bleed to post-procedural 
CPK leak, or NQWMI. Most PCI trials reported the relative 
occurrence of NQWMI to QWMI in the range of 4:1 [18] to 
15:1 [19]. Hence, it is possible that the clinical (not numeric) 
impact of bleeding events and thrombocytopenia overrides 
the impact of ischemic events.  
  The OASIS investigators [20] compared the safety and 
efficacy of fondaparinux versus enoxaparine in a cohort of 
20,000 patients with ACSWSTE. Major and minor bleeding 
was associated with a relative risk of 30-day mortality of 6.5 
(95% CI 5.1-8.2) and 3.0 (95% CI 2.1-4.3) respectively. 
Bleeding was also associated with increased incidence of 
stroke. 
  Society of Coronary Angioplasty and Interventions regis-
try report suggests [21] that the use of GPI nearly doubles 
the bleeding complications. In a report by Moscucci based 
on data from the Global Registry of Acute Coronary Events 
(GRACE) registry, the overall incidence of major bleeding 
was 3.9% [4.8% in patients with ST elevation myocardial 
infarction (STEMI), 4.7% in patients with non-ST elevation 
myocardial infarction (NSTEMI) and 2.3% in patients with 
unstable angina]. Even, after adjusting for co-morbidities 
major bleeding was an independent predictor of in hospital 
death (adjusted odds ratio 1.64, 95% confidence interval 
1.18, 2.28). Major bleeding occurred most frequently from 
gastrointestinaltract(31.5%)and vascular access site (23.8%) 
and was associated with an increased incidence of case fatal-
ity rate (18.6 vs. 5.2% p<0.001). Certain bleeding complica-
tions like retroperitoneal bleed [22], or hemorrhagic stroke 
[23] have a clear relation to GPI use. Predictors of bleeding 
are: age [24], female sex, renal dysfunction [25,26], history 
of bleeding, heart failure, and the use of GPI, and other inva-
sive procedures. In some of these hemorrhagic complica-
tions, excessive dosing [27] of anti-coagulation and GPIs 
may have been a contributing factor. 
  Excess of vascular complications (which can reach 2.9%) 
with the use of GPI [28,29] has been reported. Predictors of 
vascular complications, were similar to those of bleeding 
complication (age, female sex, body surface area <1.6, con-
gestive heart failure, chronic obstructive pulmonary disease, 
renal failure, lower extremity vascular disease, bleeding dis-
orders, emergent priority, myocardial infarction, shock, high 
risk coronary lesions). Unfortunately arteriotomy closure 
devices have not reduced the rate or severity of vascular 
complications [30]. 
Thrombocytopenia 
  Thrombocytopenia occurs fivefold more frequently with 
abciximab [31-33] than with the 2 other agents. Mild 
(<100,000), Severe (<50, 000), and profound (<20,000), oc-
cur at 4.2%, 0.7% - 1.5% and 0.4% respectively. The inci-
dence of thrombocytopemia with eptifibatide and tirofiban is 
substantially lower (<0.2%). With second abciximab admini-
stration [34] thrombocytopenia is even more common (3.5-
6.3%) and profound (2.0% <20,000 platelets). The duration 
of abciximab therapy correlates with incidence of thrombo-
cytopenia. One center (n=300) reported the 6% thrombocy-
topenia with the use of abciximab [35]. Cases of abciximab 
induced profound thrombocytopenia occurring 4 days post 
PCI [36] are of considerable concern.  
  Three abciximab [37] trials demonstrated that 2.4% of 
7,290 patients developed thrombocytopenia, and experienced 
>12-fold higher 30-day mortality rate (8.4% vs. 0.6%, re-
spectively; P <0.001). Another pooled- analysis of 3 large 
RCTs of abciximab thrombocytopenia occurred in 3.7% 
(95% CI: 3.2%, 4.2%) of abciximab-treated, patients and in 
1.8% (95% CI: 1.3%, 2.3%) of placebo-treated patients (p < 
0.001). Patients with thrombocytopenia had significantly 
higher rates of major bleeding, major hemoglobin reduction 
and increased transfusion requirements of both blood and 
platelets compared with those without thrombocytopenia. 
  In a retrospective analysis [38] of the CADILLAC data, 
50 of 1,975 qualifying patients (2.5%) who underwent pri-
mary PCI acquired thrombocytopenia. Patients who devel-
oped thrombocytopenia had higher in-hospital rates of major 
hemorrhagic complications (10.0% versus 2.7%, p = 0.01), 
greater requirement for blood transfusions (10.0% versus 
3.9%, p = 0.05), longer hospital stay (median 4.8 versus 3.6 
days, p = 0.008), and increased costs (median dollar 14,466 
versus dollar 11,629, p = 0.001). All-cause mortality was 
markedly increased at 30 days (8.0% versus 1.6%, p = 
0.0008) and at 1 year (10.0% versus 3.9%, p = 0.03). Throm-
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  Patients who developed thrombocytopenia during treat-
ment with orbofiban (0.92% of the treated cohort) had higher 
rates of death (11.6% vs. 1.7%, p < 0.001), recurrent MI 
(12.1% vs. 2.8%, p < 0.001), intracranial hemorrhage (2.9% 
vs. 0.0%, p < 0.001), and major or severe bleeding (19.0% 
vs. 2.0%, p < 0.001) at 30 days [40].  
RECENT TRIALS 
ACUITY [18] Trial 
  ACUITY (Acute Catheterization and Early Intervention 
Triage Strategy) assessed safety and efficacy of PCI in 
13,819 patients with ACSWSTE using three pharmacother-
apy strategies: bivalirudin alone, bivalirudin with GPI, and 
heparin or enoxaparine with GPI. In 9,207 who were as-
signed to GPI mortality benefit was not observed. Moreover, 
there was no reduction in ischemic events, NQWMI or 
QWMI in the GPI arms. The arm receiving bivalirudin re-
ported 3% major and 12.8% minor bleeding. Incidence of 
major and minor bleeding escalated to 5.3% and 21.7% re-
spectively when GPI was added to bivalirudin. Similar 
bleeding rates (5.7% and 21.6% respectively) were reported 
when GPI was added to heparin or enoxaparine. Importantly, 
the duration of GPI administration was relatively abbreviated 
prior to PCI (5 hours). The lack of benefit of GPI before PCI 
or after PCI was even more pronounced in subset patients 
with pre-PCI treatment of clopidogrel. 
STEEPLE [41] Trial 
  This trial enrolled 3528 patients undergoing non-
emergent femoral access PCI. The study excluded patients 
who were at higher risk for bleeding complications. Patients 
were assigned to 2 enoxaparine arms (0.5mg/k and 0.75 
mg/kg) or heparin arm. In all study arms, major and minor 
bleeding events nearly doubled with the use of GPI (from 
4.1%, 3.6% and 6.8% to 8.6%, 10.8% and 11.2% respec-
tively. 
COST EFFECTIVENESS 
  Since homogenous efficacy is conditional and germane to 
any cost-effective analysis, cost effectiveness is extremely 
difficult to ascertain. Most cost-effectiveness studies have 
not determined the cost of mortality reduction. Instead these 
studies focused on preventing merely ischemic events 
[42,43] or combination of ischemic events and mortality[44] 
and have not disclosed the entire spectrum of adverse events 
of GPI on clinical outcome[45]. The health benefits of reduc-
ing CPK leaks or NQWMI is difficult to define. These re-
ports may have miscalculated the impact of NQWMIs, major 
and minor bleeding events, and thrombocytopenia when as-
sessing the “net clinical benefit”. A favorable “net-clinical 
benefit” can probably be demonstrated for high-risk PCI 
patients, without clopidogrel pre-PCI loading, who have low 
bleeding and thrombocytopenia propensity. Recent cost-
analysis reports suggest that the mere use of bivalirudin may 
render GPI a surplus [46-48]. 
CURRENT PCI GUIDELINES 
Elective PCI 
  The European guidelines [49] suggest that GPI should 
not be routinely used for PCI of stable angina pectoris and 
should be applied selectively to patients who undergo com-
plex or high risk PCI. The American guidelines [50] state 
that it is reasonable to use GPI in stable coronary syndromes 
[Class IIa recommendation, level of evidence (LOE) B]. 
Acute Coronary Syndromes Without ST Elevation 
(ACSWSTE) 
 The European guidelines suggest that GPI (tirofiban and 
eptifibatide) could be given prior to angiography (upstream) 
to high risk patients with ACSWSTE who are subject to 
early “invasive approach” (early cardiac catheterization and 
revascularization). These guidelines also suggest that GPI 
(abciximab and eptifibatide) can be given in the cardiac 
catheterization laboratory if angiography is planned within 
<2.5 hours. The American guidelines suggest (class I rec-
ommendation LOE-A) that all patients with ACSWSTE un-
dergoing PCI without clopidogrel, should receive GPI (ab-
ciximab, tirofiban or eptifibatide); while those who have 
received clopidogrel should be considered for GPI (Class IIa, 
LOE-B).  
In ST Elevation MI (STEMI) 
  Abciximab (Class IIa, LOE-B) or tirofiban or eptifibatide 
(Class IIb LOE-C) are optional by both the American and 
European guidelines.  
The European guidelines also endorse Bivalirudin as the 
anti-thrombin of choice whether or not GPI are given.  
The use of GPI for the following indications is discouraged: 
1. Adjunctive therapy for fibrinolysis in acute myocardial 
infarction 
2. Adjunctive therapy to patients with ACS without ST-
elevation who are treated with medical therapy, and are 
not candidates for PCI.  
3. Primary or secondary prevention [51].  
  Although there are considerable similarities between the 
European and the American guidelines there is profound 
difference between the use of GPI during PCI in the USA 
(68% according to the ACC registry) and Europe (23% ac-
cording to the 2006 Euro-Heart Survey).  
CHANGES IN TREATMENT STRATEGY 
Should we Use it at all (Table 2)?  
  In view of current current data, the answer to this ques-
tion is not at all clear. Since the relative ischemic benefits 
should clearly outweigh the bleeding risk to justify the deci-
sion to initiate or continue GPI therapy. The patients who 
benefit the most from GPI are patients identified as “high 
risk” by currently available risk scales ACSWSTE [52], 
STEMI, cardiogenic shock [53], or complex elective PCI 
[54]. Also at risk are diabetics [55-57], patients with chronic 
renal insufficiency and heart failure. GPI do not seem to fa-
vorably affect PCI of degenerated vein grafts [58,59], or 
rotational atherectomy [60]. Female patients derive very lit-
tle benefit from GPI [61]. 
  Patients who are at high risk of bleeding (elderly, chronic 
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males [61], or anemia of unknown cause) should avoid GPI 
or minimize drug exposure time.  
  Clopidogrel pre-PCI treatment [62], by reducing peri-
procedural NQWMI, can potentially minimize the incre-
mental benefit of GPI [63]. Indeed for elective low-to-
intermediate risk PCI, after pretreatment with 600 mg of 
clopidogrel, abciximab was associated with no measurable 
clinically benefit within the first 30 days after PCI [64]. 
However patients with acute coronary syndromes of moder-
ate to high risk still derived some benefit from abciximab 
when superimposed on loading dose (600 mg) of clopidogrel 
[65].  
Routine Upstream Use? 
  In the ACUITY trial [66] routine administration of up-
stream GPI in a moderate to high risk cohort of ACSWSTE 
undergoing PCI when compared to in-lab administration 
resulted in excessive GPI use (98.3% versus 55.7%) longer 
duration of administration (median, 18.3 versus 13.1 hours; 
P<.001) excessive 30-day rates of major bleeding (6.1% ver-
sus 4.9% P<.001) and mild reduction of ischemic end points 
(7.1% vs. 7.9%, relative risk 1.12; 95% confidence interval, 
0.97-1.29; P = .044) and similar rates of net clinical out-
comes (11.7% vs. 11.7%; P<.001 for noninferiority; P = .93 
for superiority). The authors concluded that routine upstream 
GPI use is not justified in this cohort of patients.
  In STEMI a meta-analysis of 6 randomized trials, early 
(upstream) administration of GPI in STEMI appeared to im-
prove coronary patency with favorable trends for clinical 
outcomes [67]. However the favorable effect of upstream 
administration on mortality or meaningful clinical events, 
did not reach statistical or clinical significance.  
  Even with upstream GPI and invasive approach the TIMI 
-18 –TACTICS investigators [68] were not able to demon-
strate mortality benefit at 30 days (1.6 vs. 2.2, p=0.29) or at 6 
months (3.5 vs. 3.3%, p= 0.74).  
Which drug ? 
  Although comparative analysis between trial results [4], 
and certain trials suggested superiority of one agent over the 
other [69] this advantage did not translate into a meaningful 
superiority of any agent in a head-to-head randomized con-
trolled trial [70-72]. The advantages of Integrilin over ab-
ciximab are:  
1) Better safety profile: lower rate of allergic reactions, 
thrombocytopenia [35]  
2) Reduced cost (especially if used as bolus only results in 
considerable savings)  
3) Effects of the drug are terminated faster (shorter biologic 
half life) 
4) The drug can be re-administered without safety or efficacy 
issues. 
5) Ease of use (no specific filter)  
  The advantage of Integrilin over Tirofiban is more exten-
sive experience for in-lab use in RCTs. Some studies suggest 
that with current dosing more patients achieve “target” plate-
let inhibition [73,74] with integrilin or abciximab than with 
tirofiban.  
Table 2.  GPI Administration Based on Non-Validated Bleeding Propensity Score 
(Bleeding score:low<3;      moderate 3-5;high risk6) 
Age>80 – 3 points      Recent (<3 months) bleeding- 6 points 
Age>65- 2 point      Remote (>3months) bleeding or previous PCI bleed– 2 points 
Creatinine>2mg/dl- 2 points    Compensated heart failure – 1 points 
Dialysis- 3 points      Anemia Hemoglobin <10- 3 points 





High risk or Complex 
Elective PCI 
ACSWSTE




35 -70 u/kg UFH 
or Bivilirudin 
35-70 u/kg UFH 
GPI 
or Bivilirudin 
70 u/kg UFH 
GPI 
or Bivilirudin 
70 u/kg UFH 
GPI 
or Bivilirudin 
Moderate bleeding score 
(3-5 points) 
35 u/kg UFH \ 
or Bivilirudin 
35 u/kg UFH  
GPI^  
or Bivilirudin 
35 u/kg UFH 
GPI^  
or Bivilirudin 
70 u/kg UFH 
GPI^ 
or Bivilirudin 
High bleeding score 
(>5 points) 
35 u/kg UFH  
or Bivilirudin 
35 u/kg UFH   
or Bivilirudin 
35 u/kg UFH  
or Bivilirudin 
70 u/kg UFH 
or Bivilirudin 
ACSWSTE- acute coronary syndrome without ST elevation.    
*STEMI- ST elevation myocardial infarction (May change with the results of HORIZON-AMI study)  
 Non-validated bleeding propensity score. 
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The Dose 
  Bleeding events tend to correlate more with the duration 
of administration of GPI and anti-coagulation and with the 
intensity of anti-coagulation [75] than with the dose of GPI. 
One retrospective study suggested that GPI overdosing may 
be a contributor to bleeding complications [27]. Short term 
use of high doses of GPI [76] or inadvertent iatrogenic over-
dose is rarely associated with toxicity or bleeding. Intra-
coronary administration of eptifibatide [77] and abciximab 
have been described as safe, however the advantage of this 
method over conventional intra-venous administration is not 
proven. Studies using both intra-venous [78] and oral [1] 
prolonged administration demonstrate unfavorable clinical 
outcome.  
  The GOLD study reported correlation between insuffi-
cient platelet inhibition and excess of ischemic events. How-
ever, the unresponsive arm of GOLD had event rates that far 
exceeded event rates without GPI in most RCTs [79]. The 
preferred way to assess platelet inhibition, target value of 
platelet inhibition, and algorithms for dose adjustment have 
never been widely assessed, confirmed, and applied to clini-
cal practice. Moreover, the correlation between the extent of 
platelet inhibition and clinical efficacy are very loosely asso-
ciated [80]. 
Dose and Duration of Anticoagulation 
  PCI has advanced to the stage the major ischemic com-
plications are rare and related to suboptimal patient and le-
sion selection, procedural technique and procedural results. 
The effects of the dosage and brand of anti-coagulant on 
ischemic complications are not scientifically compelling. 
However the decision whether to use an anticoagulant, at 
what dose and for what duration have far-reaching conse-
quences on bleeding complications.
  There is emerging body of evidence suggesting that PCI 
can be executed with low dose heparin [81] or no heparin at 
all [82]. A recent RCT study (CIAO presented in TCT 2006 
by Stabile et al.) showed that PCI can be performed safely 
with no heparin or GPI. In patients with high bleeding pro-
pensity low doses of short acting anti-thrombin agents 
should be used [83].  
The Decision to Administer GPI Post PCI 
  The duration of GPI administration and anti-coagulation, 
correlates with both bleeding complications and costs. The 
optimal duration for post PCI administration was never sub-
ject to rigorous trials. However certain randomized single 
center trials were able to demonstrate similar efficacy and 
better safety when eptifibatide [84] tirofiban [85,86] or ab-
ciximab [87] were given as a single bolus or discontinued 
post PCI. Many physicians believe that post- PCI GPI ad-
ministration should we carefully assessed in view of the pro-
cedural result, the state of access sites, and patients’ bleeding 
propensity. Since access site bleeding along with gastrointes-
tinal bleeding are the most frequently encountered bleeding 
sites, these sites should be carefully inspected for bleeding. 
The physician must understand that timely discontinuation of 
GPI is crucial in a bleeding patient. By enlarge being cau-
tious and employing conservative in post-PCI GPI admini-
stration is advised for patients with intermediate-high bleed-
ing propensity. 
SUMMARY
  In view of questionable mortality benefit, and evidence 
suggesting reduced ischemic events but excessive bleeding 
vascular and thrombocytopenia complications the clinician 
should carefully and individually decide on the use GPI 
along with other adjunctive pharmacotherapy. Decision re-
garding when to initiate and terminate the GPI therapy, at 
what dose, should be based on individual patient risk versus 
benefit.  
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